Categories
BRI Director

Ursula Kaiser, MD

Early in medical school, I became fascinated by the feedback loops of endocrinology and by the many systems affected by hormones, and was quickly convinced that endocrinology was my calling. 

Ursula Kaiser, MD, Director, Brigham Research Institute

Dr. Kaiser’s research focuses on understanding the molecular mechanisms by which pulsatile gonadotropin-releasing hormone (GnRH) specifically and differentially regulates the expression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) genes. The processes of reproduction are critically dependent on the precise episodic and periodic timing of the release of these hormones, which are in turn required for gametogenesis and gonadal steroidogenesis. The hypothalamic neuropeptide, GnRH, is released in a pulsatile fashion and transported to the anterior pituitary, where it binds to specific, high affinity receptors (GnRHR) on gonadotropes. The frequency and amplitude of pulsatile GnRH release varies temporally and developmentally, and this variation is critical for normal reproductive maturation and function. Varying patterns of pulsatile GnRH differentially regulate LH and FSH biosynthesis and secretion. This raises the question which Dr. Kaiser’s laboratory is addressing: how does a gonadotrope respond to varying frequencies of pulsatile GnRH with differential LH and FSH production?

Dr. Kaiser is using three approaches to address this question. First, critical cis-acting elements in the LH and FSH subunit genes that mediate GnRH responses, and the cognate trans-acting factors that bind to these elements, have been identified. These elements and factors are distinct among the gonadotropin genes. Studies are underway to determine the mechanisms by which these factors act and interact to mediate transcriptional responses to pulsatile GnRH. Second, a perifusion system has been established and is used to delineate the intracellular signal transduction pathways by which pulsatile GnRH acts to regulate gonadotropin gene expression. Third, because GnRHR concentration, a critical determinant of gonadotrope responsiveness, varies in response to different frequencies of pulsatile GnRH, studies to understand the mechanisms of regulation of GnRHR gene expression itself by GnRH are being performed using cell models and transgenic, and knock-in mouse models.

Finally, another goal of the laboratory is to identify genetic mutations occurring in patients with defects in neuroendocrine control of reproduction. In particular, the effects of newly identified mutations in the GnRHR in patients with hypogonadotropic hypogonadism on signal transduction and on gonadotropin subunit gene expression are studied, providing unique structure-activity information on GnRH action and GnRHR function, and potential insights into pathways of GnRH regulation of FSH and LH biosynthesis and secretion. An additional new avenue of investigation by Dr. Kaiser is the characterization of the functional role of the G protein-coupled receptor, GPR54, and its cognate ligand, kisspeptin, in the regulation of GnRH release and action in the neuroendocrine regulation of reproductive function. This gene was recently recognized to be critical in the regulation of reproductive maturation and function based on the identification of mutations therein in patients with hypogonadotropic hypogonadism.

Under the guidance of Dr. Kaiser, research fellows will develop specific research hypotheses pertinent to Dr. Kaiser’s research program. Together with Dr. Kaiser, they will design studies to address these hypotheses, learn the necessary techniques to complete the studies, perform these studies, and analyze the results. As necessary, they will learn how to trouble-shoot the methodologies, revise the experimental approaches, and re-evaluate their original hypotheses. These studies involve primarily bench work, using basic techniques of molecular and cellular biology in vitro and in cell models, as well as transgenic, knock-out, and knock-in murine models. Fellows meet on a formal basis for an hour each week with Dr. Kaiser to discuss progress, review results, and for mentorship and career guidance, as well as informally daily as needed. Fellows also have the opportunity to hone their presentation skills at a weekly lab meeting, and also more formally at a weekly Division Research Seminar Series. Fellows also participate in a journal club to review articles relevant to their studies and to learn how to critically evaluate the literature. Fellows are encouraged to prepare manuscripts and to write grants for continued funding in close collaboration with Dr. Kaiser. The goal of this training is to give fellows the skills to become independent researchers.

Categories
BRI Past-Director ROC Department Representative

Thomas S. Kupper, MD

Categories
BRI Past-Director ROC Department Representative

Cynthia Morton, PhD

Highlights from the BRI Director (2008-2010)

The Brigham Research Institute conducted strategic planning exercises with the Research Oversight Committee, leading to the development of strategic themes and priorities for the BRI that included:

  • Shared Mechanisms of Disease
  • Personalized Medicine
  • Targeted Therapeutical
  • Health Disparities
  • Comparative Effectiveness

As part of the goal of increasing attendance at the BRI’s monthly forum, it was rebranded as part of the successful Research Connection E-Mail Series, which is distributed weekly to the research community. The BRI collaborated with the Center for Clinical Investigation (CCI), Office for Research Careers and Research Operations to thoroughly promote these monthly lunches, which attract standing-room only crowds.

Brigham Research Institute staff worked closely with the CCI and Harvard Catalyst to communicate significant grants and resources available to investigators, particularly junior investigators, when Catalyst launched and throughout the academic year.

A town hall meeting was organized to deliver up-to-the-minute information on the American Recovery and Reinvestment Act (ARRA).

Categories
BRI Co-Director

Charles N. Serhan, PhD, DSc

Charles Serhan, PhD, DSc, is the Simon Gelman Professor of Anaesthesia (Biochemistry and Molecular Pharmacology) at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine. He is Director of the Center for Experimental Therapeutics and Reperfusion Injury at the Brigham. In 1987, he joined the faculty at Harvard Medical School in 1987 and received an honorary degree from Harvard University (1996). He has received several awards including an NIH MERIT award (2000) and has delivered more than 50 keynote and plenary lectures. 

Among these, 2008 William Harvey Outstanding Scientist Medal and AAAS Fellow in 2011. In 2010, he received the Society for Leukocyte Biology Bonazinga Award for outstanding research on leukocytesThe American College of Rheumatology Hench (Nobel Laureate) Award Lecture in 2011 and is a Mérieux 2013 Laureate. In 2016, he received the IUBMB Lecture Metal and the Ross Prize in Molecular Medicine. In 2017, he received the International Eicosanoid Research Foundation’s Lifetime Achievement Award and the American Society of Investigative Pathology (ASIP) 2018 Rous Whipple Award.

Dr. Serhan has over 25 years of experience leading multidisciplinary research teams and led as Principle Investigator/Program Director Program (PI/PD) Project “Molecular Mechanisms in Leukocyte-Mediated Tissue Injury” (P01-DE13499), PI/PD for “Specialized Center for Oral Inflammation and Resolution” (P50-DE016191) and currently is the PI/PD of “Resolution Mechanisms in Acute Inflammation: Resolution Pharmacology” (P01-GM095467) a program project grant supported by NIH/NIGMS. Importantly, he is hands-on at the bench and has trained > 60 fellows and trainees that has successful careers in academic medicine and industry.

Current research in the Serhan laboratory focuses on structural elucidation of novel bioactive molecules that activate the resolution of inflammation. Our overall mission is “To identify novel mediators, pathways, and their cellular receptors and targets critical in promoting resolution of inflammation and reperfusion tissue injury and establish their relation to human disease.” Our ongoing studies focus on structural elucidation of novel molecules and pathways that are pro-resolving and endogenous anti-inflammatory chemical signals.

We elucidated new super-families of lipid-derived chemical mediators, coined Resolvins and Protectins, and Maresins, that stimulate resolution of inflammatory responses and reduce pain. Several of these molecules help clear bacteria and stimulate tissue regeneration. We’ve designed novel therapeutic approaches using these structures as biotemplates. New therapeutic approaches built with the knowledge of these signaling pathways could be more potent, selective and better tolerated since they are based on structures naturally evolved in these processes. Several of these new designer pro-resolving therapeutics have already been shown effective in humans.

Categories
BRI Executive Committee Education

Paul Anderson, MD, PhD

He is the K. Frank Austen Professor of Medicine at Harvard Medical School and the associate chief of the Division of Rheumatology, Inflammation, and Immunity at Brigham and Women’s Hospital.

He is a member of the American Society for Clinical Investigation and the Association of American Physicians and serves on the Scientific Advisory Committee at the American College of Rheumatology. Before graduating from the medical scientist training program at the New York University School of Medicine, Anderson trained with Jan Vilcek, MD, PhD, the inventor of Remicaid, the first biologic therapy for patients with autoimmune disease. Anderson then came to the Brigham where he completed an internship and residency in Internal Medicine and a fellowship in Rheumatology. In 1990 he started his own research laboratory at the Brigham focusing on the role that post-transcriptional control of gene expression plays in the regulation of inflammatory and stress response programs. His laboratory has been funded by the NIH and by various foundations and industry collaborations, and has hosted more than 30 MD and/or PhD research fellows.

He has authored or co-authored more than 175 publications and is on the editorial boards of a number of journals, including Cellular Immunology and Modern Rheumatology. In addition, Anderson is a senior physician at the Brigham and sees patients in the Brigham arthritis ambulatory clinic and attends on the Rheumatology consult service. He is a member of the Rheumatology Division Fellowship Selection Committee, which interviews all applicants for the Rheumatology Fellowship Program and makes recommendations for ranking these candidates.

Anderson received a BS in Biology from SUNY Stony Brook, and received both MD and PhD (Microbiology) from New York University School of Medicine.

Categories
BRI BRI Executive Committee

Jacqueline M. Slavik, PhD, MMSc

Categories
BRI Past-Director People

Marc Sabatine, MD, MPH

Highlights from the BRI Director 2018-2020

During Fiscal Year 2019, the Brigham Research Institute provided support to activities defined through a BRI-wide strategic assessment and planning process the previous year. Research Roundtables, thematic discussions focused on areas aligned with programs/centers to define priorities in those areas and foster innovation and collaboration.

The BRI distributed $3.22 Million in internal awards in FY2019. These awards ranged from $500 poster awards to the $500,000 BRI Director’s Transformative Award. The BRI implemented the solicitation and selection process for the newly launched President’s Scholar Awards, intended to support and recognize Assistant or Associate Professors at the Brigham who have made outstanding contributions to their chosen field of research and who have demonstrated exceptional potential.

We continued hosting bi-annual research faculty and trainee lunches and in 2019, hosting two lunches for each group:

  • Postdocs and Trainees
  • Instructors
  • Assistant Professors
  • Associate Professors
  • Professors

Our Scientific Advisory Board added a new member, now comprised of nine highly accomplished scientific and industry leaders who provide guidance to enrich our strategies to promote biomedical advances at the Brigham. The Board meets annually.

The BRI launched a new monthly newsletter, Science Spotlight, to celebrate Brigham faculty publications in high impact journals and keep the research community informed about the work of their peers.

Brigham researchers published more than 9,400 publications in 2019 (ranking second among healthcare institutions in the world in terms of total article count, according to Nature Index), with close to 500 of these in top-rated journals.

Brigham research revenue was $698 Million in FY2019, representing nearly a quarter of the hospital’s revenue.